Transparency Notification - Seite 2

B)     Voting rights	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
	TOTAL			0	0.00%
	TOTAL (A+B)			# of voting rights	% of voting rights
			CALCULATE	19,600,098	19.66%

      ·Full chain of controlled undertakings through which the holding is effectively held: Cosmo Technologies Ltd is a 100% subsidiary of Cosmo Pharmaceuticals N.V.

3. Miscellaneous
   • This press release is available on Acacia Pharma Group plc’s website (https://acaciapharma.com/investors/regulatory-announcements)
   • The notification may be found on Acacia Pharma Group plc’s website ((https://acaciapharma.com/investors/regulatory-announcements)

Contacts

Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO [phone] / [phone] [e-mail]	International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson [phone] [e-mail]
US Investors LifeSci Advisors Irina Koffler [phone] [e-mail]	Media in Belgium and the Netherlands Chris Van Raemdonck [phone] [e-mail]

Acacia Pharma Group plc
The Officers’ Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom